Case Studie

Accelerating access through strategic investment cases

MMGH develops investment cases to accelerate access to new vaccines, particularly for diseases disproportionately affecting low- and middle-income countries.

These investment cases provide structured, evidence-based justifications for prioritizing investment in promising vaccine products.

They aim to catalyze alignment across global health stakeholders with different perspectives, including funders, manufacturers, policymakers, and implementers, by combining robust demand projections, market viability assessments, delivery feasibility, and financing strategies.

MMGH has served as a technical lead in the development of multiple investment cases for high-priority vaccine and products. Our team designs comprehensive frameworks that connect supply-side considerations (e.g., manufacturing, pricing) with delivery and uptake realities in LMICs. We work closely with key stakeholders to develop a shared understanding of product potential, enabling better coordination and decision-making.

Key Activities

Ícone

Defined potential use cases by conducting landscape analyses, interviews, expert workshops, and surveys across regions and priority populations.

Ícone

Identified delivery challenges, such as cold chain limitations or healthcare worker training needs, and mapped enabling conditions for successful uptake.

Ícone

Modeled a range of demand scenarios based on population health needs, delivery channels, policy factors, and behavioral assumptions; characterized key uncertainties affecting uptake and scale.

Ícone

Conducted discounted cash flow and breakeven pricing analyses to evaluate commercial viability under different demand and cost structures.

Ícone

Supported academic institutions in estimating population health impact (e.g., DALYs averted) and economic returns on investment.

Ícone

Facilitated alignment with amongst key stakeholders to ensure key findings and conclusions are linked with actionable next steps.

Outcomes

MMGH’s investment cases informed funding and access strategies for high-priority products, including MR-MAPs and influenza vaccines, supporting early-stage product positioning and accelerating progress toward availability in LMICs.

Read more about our work:

Impact and cost-effectiveness of measles vaccination through microarray patches in 70 low-income and middle-income countries: mathematical modelling and early-stage economic evaluation

GO TO PUBLICATION

Estimating the future global dose demand for Measles-Rubella microarray patches

GO TO PUBLICATION

Contact the MMGH Team

To find out how we can assist with your upcoming projects, please fill in this form and someone from our team will contact you shortly.

Headquarters

MMGH Consulting GmbH Kuerbergstrasse 1 8049 Zurich, Switzerland

+41 44 553 04 53

Branch

MMGH Consulting GmbH Kuerbergstrasse 1 8049 Zurich, Switzerland

+41 22 596 78 60